1-8 of 8
Massimo Broggini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Free
Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas, Ivo Kwee, Petra Hillmann, Andrea Rinaldi, Luciano Cascione, Filippo Spriano, Elena Bernasconi, Francesca Guidetti, Laura Carrassa, Roberta Bordone Pittau, Florent Beaufils, Reto Ritschard, Denise Rageot, Alexander Sele, Barbara Dossena, Francesca Maria Rossi, Antonella Zucchetto, Monica Taborelli, Valter Gattei, Davide Rossi, Anastasios Stathis, Georg Stussi, Massimo Broggini, Matthias P. Wymann, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Doriano Fabbro, Francesco Bertoni
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 120–129.
https://doi.org/10.1158/1078-0432.CCR-17-1041
Published: 02 January 2018
View articletitled, PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Open the PDF for PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter

Free
Lorenza Rimassa, Jordi Bruix, Massimo Broggini, Armando Santoro
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4290.
https://doi.org/10.1158/1078-0432.CCR-13-1321
Published: 31 July 2013
View articletitled, Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter
Open the PDF for Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter in another window
Journal Articles

Analysis of Gene Expression in Early-Stage Ovarian Cancer

Free
Sergio Marchini, Pietro Mariani, Giovanna Chiorino, Eleonora Marrazzo, Riccardo Bonomi, Robert Fruscio, Luca Clivio, Annalisa Garbi, Valter Torri, Michela Cinquini, Tiziana Dell'Anna, Giovanni Apolone, Massimo Broggini, Maurizio D'Incalci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7850–7860.
https://doi.org/10.1158/1078-0432.CCR-08-0523
Published: 01 December 2008
View articletitled, Analysis of Gene Expression in Early-Stage Ovarian Cancer
Open the PDF for Analysis of Gene Expression in Early-Stage Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil

Free
Monica Ganzinelli, Laura Carrassa, Francesca Crippa, Michele Tavecchio, Massimo Broggini, Giovanna Damia
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5131–5141.
https://doi.org/10.1158/1078-0432.CCR-08-0304
Published: 12 August 2008
View articletitled, Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil
Open the PDF for Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil in another window
Journal Articles

PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth

Free
Federica Polato, Annamaria Codegoni, Robert Fruscio, Patrizia Perego, Costantino Mangioni, Saurabh Saha, Alberto Bardelli, Massimo Broggini
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 6835–6839.
https://doi.org/10.1158/1078-0432.CCR-04-2357
Published: 03 October 2005
View articletitled, PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth
Open the PDF for PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth in another window
Journal Articles

Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs

Free
Faina Vikhanskaya, Mobin M. Siddique, Ming Kei Lee, Massimo Broggini, Kanaga Sabapathy
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (12): 4348–4356.
https://doi.org/10.1158/1078-0432.CCR-04-1547
Published: 15 June 2005
View articletitled, Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs
Open the PDF for Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs in another window
Journal Articles

Enhancement of in Vivo Antitumor Activity of Classical Anticancer Agents by Combination with the New, Glutathione-Interacting DNA Minor Groove-Binder, Brostallicin

Free
Maria Antonietta Sabatino, Tina Colombo, Cristina Geroni, Sergio Marchini, Massimo Broggini
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5402–5408.
Published: 12 November 2003
View articletitled, Enhancement of in Vivo Antitumor Activity of Classical Anticancer Agents by Combination with the New, Glutathione-Interacting DNA Minor Groove-Binder, Brostallicin
Open the PDF for Enhancement of in Vivo Antitumor Activity of Classical Anticancer Agents by Combination with the New, Glutathione-Interacting DNA Minor Groove-Binder, Brostallicin in another window
Journal Articles

Cooperation between p53 and hMLH1 in a Human Colocarcinoma Cell Line in Response to DNA Damage

Free
Faina Vikhanskaya, Gennaro Colella, Monica Valenti, Silvio Parodi, Maurizio D’Incalci, Massimo Broggini
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (4): 937–941.
Published: 01 April 1999
View articletitled, Cooperation between p53 and hMLH1 in a Human Colocarcinoma Cell Line in Response to DNA Damage
Open the PDF for Cooperation between p53 and hMLH1 in a Human Colocarcinoma Cell Line in Response to DNA Damage in another window